A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We conducted a phase I safety and pharmacokinetic study of molnupiravir...

Full description

Bibliographic Details
Main Authors: Keisuke Nakamura, Katsukuni Fujimoto, Chihiro Hasegawa, Ikuo Aoki, Hiroyuki Yoshitsugu, Hiroyuki Ugai, Naoyoshi Yatsuzuka, Yoshiyuki Tanaka, Kenichi Furihata, Brian M. Maas, Prachi K. Wickremasingha, Kelly E. Duncan, Marian Iwamoto, Selwyn A. Stoch, Naoto Uemura
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13395

Internet

https://doi.org/10.1111/cts.13395

Similar Items